Immune check-point in endometrial cancer

Francesca De Felice, Claudia Marchetti, Vincenzo Tombolini, P Benedetti Panici

Research output: Contribution to journalReview articlepeer-review

Abstract

BACKGROUND: Endometrial cancer (EC) is one of the most frequent tumors in women. Despite recent advances in treatment approaches, the prognosis in advanced, recurrent, or metastatic disease remains poor. The aim was to provide the clinician with an update, the current status, and the new developments in the management of EC. Based on the new EC molecular classification, we focused on the impact of immune check-point inhibitors.

METHODS: Pivotal trials, published literature, and conference proceedings were reviewed. PubMed and Scopus databases were searched to select English-language articles.

RESULTS: Immune check-point inhibitors are the subject of ongoing studies and their benefit seems to be related to microsatellite instability (MSI) status.

CONCLUSIONS: Immune check-point inhibitors should be considered a promising treatment option to better personalize therapeutic strategies in EC.

Original languageEnglish
Pages (from-to)910-916
Number of pages7
JournalInternational Journal of Clinical Oncology
Volume24
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • Antineoplastic Agents, Immunological/therapeutic use
  • Cell Cycle Checkpoints/drug effects
  • Endometrial Neoplasms/drug therapy
  • Female
  • Humans
  • Immunotherapy/methods
  • Microsatellite Instability
  • Prognosis

Fingerprint

Dive into the research topics of 'Immune check-point in endometrial cancer'. Together they form a unique fingerprint.

Cite this